Table: Otsuka Holdings -9-MTH group results (IFRS)
Oct 31 (Reuters)-
Otsuka Holdings Co Ltd
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
9 months ended 9 months ended Year to
Sep 30, 2023 Sep 30, 2022 Dec 31, 2023
LATEST YEAR-AGO COMPANY
RESULTS RESULT FORECAST
Sales 1.48 trln 1.27 trln 1.99 trln
(+16.8 pct) (+14.3 pct) (+14.2 pct)
Operating 202.65 114.85 245.00
(+76.5 pct) (-27.4 pct) (+63.0 pct)
Pretax
Net 161.71 111.04 188.00
(+45.6 pct) (-12.3 pct) (+40.4 pct)
EPS Basic 297.99 yen 204.66 yen 346.44 yen
EPS Diluted 297.99 yen 204.64 yen
Ann Div 100.00 yen 100.00 yen
-Q2 Div 50.00 yen 50.00 yen
-Q4 Div 50.00 yen 50.00 yen
NOTE - Otsuka Holdings Co Ltd.
(Figures are reported based on international accounting rules (IFRS).)
If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half
dividend and Q4 to the second-half dividend announced before a new corporate law in
2006 allowed companies to pay and report dividends on a quarterly basis.
*Net - represents Net profit attributable to owners of the parent company.
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4578.T
Recent news on Otsuka Holdings
See all newsOtsuka, Ionis' experimental ALS drug meets main goal in late-stage study
Brief: Otsuka Pharmaceutical Announces Ulefnersen Early Access Program For Eligible People Living With FUS-ALS
Brief: Otsuka Pharmaceutical Says Phase 3 Fusion Results For Ulefnersen Met Primary Endpoint
Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit In Rezilient3 Phase 3 Trial In First-Line Egfr Exon 20 Insertion Mutation Non-Small Cell Lung Cancer
Climb Bio rises after early-stage data for kidney disease drug